Alterity Therapeutics Presents New Neuroprotection Data for ATH4
Ticker: PRNAF · Form: 6-K · Filed: Oct 11, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Oct 11, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: R&D, data-presentation, foreign-private-issuer
Related Tickers: ATY
TL;DR
Alterity Therapeutics (ATY) presenting new neuroprotection data for ATH4, check the latest filings.
AI Summary
Alterity Therapeutics Ltd. announced on October 11, 2024, that new data will be presented describing the neuroprotection of ATH4. This information is being filed as a Form 6-K, which is a report of foreign private issuers.
Why It Matters
This filing indicates the company is advancing its research and development for ATH4, potentially impacting its future therapeutic applications and investor outlook.
Risk Assessment
Risk Level: medium — The filing relates to R&D data presentation, which carries inherent risks associated with clinical trial outcomes and drug development.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant and subject of the filing
- ATH4 (drug_candidate) — Therapeutic agent for which new data is being presented
- October 11, 2024 (date) — Date of the announcement and filing
FAQ
What specific new data regarding the neuroprotection of ATH4 will be presented?
The filing states that new data describing the neuroprotection of ATH4 will be presented, but the specific details of this data are not included in this Form 6-K.
What is the purpose of filing this Form 6-K?
This Form 6-K is filed by Alterity Therapeutics Limited, a foreign private issuer, to report information that is made public or is required to be made public in their home country or is otherwise made public.
How does this filing relate to Alterity Therapeutics' existing registration statements?
This Form 6-K is being incorporated by reference into Alterity Therapeutics' existing Registration Statements on Form S-8 and Form F-3.
What is the company's principal executive office address?
The principal executive office of Alterity Therapeutics Limited is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Has Alterity Therapeutics changed its name or former company name recently?
The filing indicates that the former company name was PRANA BIOTECHNOLOGY LTD, with a date of name change on January 5, 2001.
Filing Stats: 198 words · 1 min read · ~1 pages · Grade level 12.8 · Accepted 2024-10-10 21:15:45
Filing Documents
- ea0217387-6k_alterity.htm (6-K) — 14KB
- ea021738701ex99-1_alterity.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-087033.txt ( ) — 35KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: October 11, 2024 2